Healthcare / Drug Manufacturers - Specialty & GenericBuenos Aires
$1625.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 13%
FCF escenarios
weak_data · normalized FCF $-31.8B · quality 35.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$131.2B
P/E
8.2x
↓EV/EBITDA
10.9x
↓ROE
3.4%
↑Gross Margin
60.8%
↑Debt/Equity
2.69
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+30.1%
FCF CAGR
—
FCF margin
-41.4%
FCF / Net income
-16.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $126.73B · net income $3.09B · FCF $-52.46B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $126.73B | $126.73B | $120.75B | $84.99B | $57.52B |
| Net Income | $3.09B | $3.09B | $31.37B | $-23.63B | $508.9M |
| EBITDA | $33.64B | $33.64B | $56.18B | $-13.68B | $9.22B |
| EPS | 38.24 | 38.24 | 388.45 | -292.62 | 6.30 |
| Gross Margin | 60.8% | 60.8% | 54.5% | 52.7% | 47.3% |
| Operating Margin | 26.1% | 26.1% | 17.4% | 13.4% | 16.1% |
| Net Margin | 2.4% | 2.4% | 26.0% | -27.8% | 0.9% |
| Balance Sheet | |||||
| Debt/Equity | 2.69 | 2.69 | 2.23 | 0.80 | 2.13 |
| Current Ratio | 0.98 | 0.98 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-52.46B | $-52.46B | $-4.19B | $-31.80B | $-36.76B |
| Returns | |||||
| ROE | 3.4% | 3.4% | 37.1% | -48.1% | 1.6% |
| Valuation | |||||
| P/E | 8.18 | 8.18 | — | — | — |
| EV/EBITDA | 10.90 | 10.90 | — | — | — |
| P/B | 1.43 | 1.43 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 4.9% | 4.9% | 42.1% | 47.8% | — |
| EPS Growth | -90.2% | -90.2% | 232.7% | -4744.8% | — |
| Dividend Yield | 1.0% | 1.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
55.6%
EPS terminal req.
$144.19
Spread vs growth
-145.8%
5Y implied EPS CAGR
35.5%
EPS terminal req.
$174.47
Spread vs growth
-125.6%
10Y implied EPS CAGR
22.1%
EPS terminal req.
$280.99
Spread vs growth
-112.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+19.1%
Start / end P/E
3.5x → 41.8x
EPS bridge
388.45 → 38.24
Residual
-991.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.